Topic: shareholder activism
The majority of investors backed a proposal that would allow Takeda to claw back executive pay should the Shire deal not live up to expectations.
After investors sent Mylan shares sharply down Tuesday, analysts wrote that there was more to the selloff than just a rough quarter.
Appaloosa's attempt to split Allergan's CEO and chair positions came up short at an investor meeting Wednesday.
More than half of Bayer shareholders gave a thumbs down to executives and their actions in 2018, the lowest approval rating for a German company since World War II.
Bayer Chairman Werner Baumann could face a vote a no confidence from its top investor, BlackRock, Reuters reported.
Allergan has been warring with investors pushing for a change to the company's leadership structure, but leading proxy adviser firms aren't on board.
Proxy adviser Glass Lewis opposes re-electing Marcus Wallenberg, a member of Sweden's powerful Wallenberg family.
Recommendations to vote “yes” from proxy advisory firms were enough to end an activist’s efforts to scuttle the BMS-Celgene merger.
When it comes to Bristol-Myers Squibb’s Celgene merger, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up.
Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed.